SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
BIOTECH: Kura Can Count on Its Cash and Experienced Leaders
A team of veteran drug hunters at Kura Oncology Inc. has licensed an old drug for new purposes, hoping to use advances in genetic sequencing to match the right drug with the right patient.
BioNano Genomics Inc., a genome mapping company in San Diego, announced the appointment of Terry Salyer as chief commercial officer.
CORRECTION: Mast Therapeutics Inc., a San Diego-based biopharmaceutical company, filed a new “shelf” S-3 registration statement totaling $166.6 million on March 24.
The UC San Diego Health System is in talks with Eisenhower Medical Center in the Coachella Valley to form a partnership that could potentially lead to the expansion of the Rancho Mirage hospital into a teaching and research hospital, according to The Desert Sun newspaper and a UCSD spokesman.
Retrophin Inc. announced the closing of its previously announced underwritten public offering of 7,866,000 shares of its common stock at a price to the public of $19 per share, including 1,026,000 shares sold pursuant to the full exercise of the underwriters’ option.
Biocept Inc., a San Diego-based molecular oncology diagnostics company, announced Tuesday that it has entered into a clinical collaboration with the University of California, San Diego Moores Cancer Center.
Shares of MEI Pharma Inc. lost more than two-thirds of their value Monday after the San Diego biotech said its cancer drug Pracinostat failed a Phase 2 clinical trial.
Mark Harrison has been appointed chief financial officer for UC San Diego Health Sciences, overseeing a budget of more than $2.4 billion for the university.
Continued population growth in the North County inland region has motivated Sharp Rees-Stealy Medical Center in Rancho Bernardo to announce plans to move to a new facility, nearly doubling the size of the existing medical center.
San Diego-based Batu Biologics Inc. announced the publication of pre-clinical data for its flagship immunotherapeutic product, ValloVax in the Journal of Translational Medicine.
San Diego-based Vital Therapies Inc., a company developing a cell-based therapy to help people suffering from serious liver disease, announced its fourth quarter financial results on March 19, reporting a net loss of about $14 million compared with a net loss of $10.2 million in the same quarter of 2013.
San Diego-based Retrophin Inc., a publicly traded biopharmaceutical company, announced that it plans to raise $130 million in a public offering of 6.8 million shares of common stock at $19 per share.
Otonomy Inc., a company that makes treatments for the middle and inner ear, announced its fourth quarter financial results on March 19, reporting a net loss of $9.8 million compared with a net loss of $7.8 million in the same quarter of the previous year.
San Diego-based Pediatric Bioscience Inc., the biotech developing blood tests for autism, has raised $1.68 million in debt financing, according to a recently amended regulatory filing.
Trovagene Inc., a developer of cell-free molecular diagnostics, announced Wednesday that Matthew L. Posard has joined the company as executive vice president and chief commercial officer.